23 hours Ago By ABMN Staff
Marshall Wace LLP decreased its stake in Olema Pharmaceuticals, Inc. ( NASDAQ:OLMA – Free Report ) by 19.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission.
The fund owned 192,943 shares of the company’s stock after selling 47,444 shares during the quarter. Marshall Wace LLP owned approximately 0.34% of Olema Pharmaceuticals worth $1,125,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. KLP Kapitalforvaltning AS purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth about $30,000. Teacher Retirement System of Texas purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth about $60,000.
Vontobel Holding Ltd. purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth about $62,000. Fox Run Management L.
L.C. purchased a new stake in shares of Olema Pharmaceuticals in the fourth quarter worth about $80,000.
Finally, SG Americas Securities LLC boosted its stake in shares of Olema Pharmaceuticals by 33.8% in the fourth quarter. SG Americas Securities LLC now owns 17,475 shares of the company’s stock worth $102,000 after buying an additional 4,419 shares during the last quarter.
Hedge funds and other institutional investors own 91.78% of the company’s stock. Analyst Upgrades and Downgrades OLMA has been the subject of a number of analyst reports.
Oppenheimer reaffirmed an “outperform” rating and issued a $25.00 price target (down previously from $30.00) on shares of Olema Pharmaceuticals in a report on Wednesday, March 19th.
HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Olema Pharmaceuticals in a report on Monday. Finally, JPMorgan Chase & Co.
reduced their price target on Olema Pharmaceuticals from $30.00 to $28.00 and set an “overweight” rating for the company in a report on Friday, March 28th.
Olema Pharmaceuticals Trading Up 3.1 % NASDAQ OLMA opened at $5.04 on Wednesday.
The stock has a 50-day moving average of $4.19 and a 200 day moving average of $6.72.
Olema Pharmaceuticals, Inc. has a twelve month low of $2.86 and a twelve month high of $16.
62. The stock has a market capitalization of $344.40 million, a price-to-earnings ratio of -2.
30 and a beta of 2.10. Olema Pharmaceuticals ( NASDAQ:OLMA – Get Free Report ) last announced its earnings results on Tuesday, March 18th.
The company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.
12. Equities analysts predict that Olema Pharmaceuticals, Inc. will post -2.
33 EPS for the current fiscal year. About Olema Pharmaceuticals ( Free Report ) Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.
Featured Stories Want to see what other hedge funds are holding OLMA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Olema Pharmaceuticals, Inc. ( NASDAQ:OLMA – Free Report ).
Receive News & Ratings for Olema Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Olema Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
